Solution for Consideration: Medical Tourism and Personal Rx Importation

Size: px
Start display at page:

Download "Solution for Consideration: Medical Tourism and Personal Rx Importation"

Transcription

1 Solution for Consideration: Medical Tourism and Personal Rx Importation

2 Agenda 1. Background information on the challenges posed by specialty prescriptions. 2. Medical Tourism; Clinical Pharma Travel Program 3. Personal Importation of Prescription

3 Medical and Prescription $7,000 $6,000 $5,000 $4,000 $3,000 $2,000 $1,000 Plan Costs $1, $1, $1, $1, $1, $1, $4, $4, $4, $4, $4, $4, % after 5 years (3.4% annually) % after 5 years (0.19% annually) $0 Jan10-Dec10 Jan12-Dec12 Jan14-Dec14 Jan10-Dec10 Jan11-Dec11 Jan12-Dec12 Jan13-Dec13 Jan14-Dec14 Jan15-Dec15 Rx Claims Cost PEPY $1, $1, $1, $1, $1, $1, Medical Claims Cost PEPY $4, $4, $4, $4, $4, $4, *includes run-out medical claims The average cost per Rx per employee has increased 38% in the past 3 years which is being driven by high cost specialty prescriptions

4 Prescription Spend by Type (Specialty vs Non-Specialty) $16,000,000 $14,000,000 $12,000,000 $10,000,000 $10,668,680 $2,588,940 $11,879,524 $3,490,901 $13,589,198 $5,346,093 $8,000,000 $6,000,000 $4,000,000 $8,079,740 $8,388,623 $8,243,105 $2,000,000 $ Non-Specialty Rx Specialty Rx *SPECIALTY Rx defined by prescriptions with an average cost over $3,000 Specialty prescriptions with an average cost over $3,000 each is the primary cost driver to the plan. These primarily include the treatment for conditions like Cancer (Oncology), Hep C, MS, Rheumatoid Arthritis, HIV

5 Drugs that cost $3k+ per script in 2015 Unique Members Unique Members Taking Specialty Drugs Total Unique Members Receiving ANY Scripts % of Total Members Receiving Rx 1.5% 1.6% 1.9% Spend Total Spend for Specialty Drugs $2,588,940 $3,490,901 $5,346,093 Total Spend for Non-Specialty Drugs $8,079,740 $8,388,623 $8,126,557 Total Rx Spend for Time period $10,668,680 $11,879,524 $13,472,650 % of Total Spend 22.4% 29.4% 39.7% Script Count # of Scripts for Specialty Drugs Total # of Scripts for Time Period % of Total 0.4% 0.5% 0.6% Avg. Cost Per Script Avg. Cost For Specialty Drugs $4, $5, $6, Avg. Cost For All Drugs $88.31 $94.22 $ Avg. Cost For All Non-Specialty Drugs $68.79 $66.85 $62.24

6 Prescription Spend Per Member Per Year $1,600 $1,400 $1,241 $1,405 $1,200 $1,000 $1,108 $269 $365 $553 $800 $600 $400 $839 $876 $852 $200 $ Non-Specialty Rx Specialty Rx Total Rx Spend Specialty prescriptions with an average cost over $3,000 each is the primary cost driver to the plan. These primarily include the treatment for conditions like Cancer (Oncology), Hep C, MS, Rheumatoid Arthritis, HIV

7 Health City Overview Health City Cayman Islands is a joint venture between Narayana Health and Ascension. Ascension is the largest faith based non-profit, healthcare system in the US. Ascension provides the highest quality care to all with special attention to those who are poor and vulnerable.

8 Examples of Contracts Royal Caribbean Cruise lines Aetna International (Finalizing Agreement) AXA Assistance USA, Inc. Best Doctors Cigna Global Health Companion Global Healthcare Med Retreat National HealthCare Solutions Ltd (NHSI) Quality Health Management LLC United Health International Inc. Rubicon Group Edison Health

9 March 2015 Clinical Pharma-Travel Program Welcome to World-Class, Destination Healthcare

10 Organization Introductory Video

11 Clinical Pharma-Travel Program Pharm-Travel is a program designed for individuals to obtain a clinical review and prescribed medical regimens for significantly reduced cost. Patients who want to or need to reduce the cost of their prescription medications patients who require expensive medications for chronic illness and long term treatment. patients who require as needed medications or a one time dose. Initial focus will be MS, Cancer, RA, HIV, Hep C

12 Clinical Pharma-Travel Program 1. Health City has an initial assessment process that qualifies each candidate for the program, and ensures that the medications are available. When potential patients are recognized as a candidate and medications are secured, patients are sent formal invitations for participation. 2. Once accepted into the program the patient travels to HCCI with their U.S. M.D. s issued prescription(s) to meet with an HCCI specialist 3. HCCI specialist reviews the patient s recent lab work and provides consultation, physical exam if required, any additional screening determined necessary to complete the process, collaborates/acknowledges the appropriateness of the medication and provides a 3 month prescription 4. Rx is filled at HCCI and brought back to the U.S. by the patient. 5. The patient travels to HCCI quarterly for subsequent RXs if needed.

13 Clinical Pharma-Travel Program: Hepatitis C Treatment Health City Cayman Islands is a state-of-the-art tertiary care hospital located in the heart of the Caribbean. HCCI believes no one s socio-economic status should determine their access to healthcare. In line with this vision and mission, HCCI is now offering the new medical treatment for Chronic active Hepatitis C, at a fraction of the US cost. Pasco School District has had at least 7 members supported by Hep C treatment at a cost of over $400,000

14 Evaluation Requirements by HCCI Medical Team during First Visit Complete medical history / records including any complications of liver disease in past, presence of significant extrahepatic disease including ascitis and symptoms of chronic HCV that may diminish quality of life. Detailed medications history is required to analyze drug interactions before dispensing Hep C medications. Any previous or present HCV treatment history with outcome / response ( example cure, resistance, virological failure to any prior Hep C drugs used).

15 INVESTIGATIONS (PREFEREBLY LESS THAN 4 WEEKS OLD) HCV genotype testing 1,2,3,4,5,6 (including subtype, e.g., 1a or 1b) (which was reported at time of initiating first treatment for Chronic Hepatitis C), because the regimes are based on genotype and subtypes PLASMA HCV RNA (quantitative viral load) preferably most recent and all the previous values. It is important to have this recent value as the treatment is initiated based on this value Hemoglobin, hematocrit, WBC with differential, and platelet counts (recent OR at least 4 weeks old) Biochemical markers of liver injury and assessment of hepatic function, including serum ALT,AST,GGT, serum albumin, serum bilirubin (total, direct and indirect direct), INR,Prothrombin time, Fasting Blood glucose (recent OR at least 4 weeks old) If above tests are not done at place of origin, will be done at HCCI at first visit

16 INVESTIGATIONS INVESTIGATIONS (PREFEREBLY LESS THAN 4 WEEKS OLD) Serum creatinine and serum electrolytes (recent OR at least 4 weeks old). Screening Hep B with Serum HBsAg. If positive for Hepatitis B, then - antihbc, antihbs HIV status (HIV 1 & 2 serology), If HIV seropositive current antiretroviral regimens used and degree of viral suppression (baseline report) Serum Creatine Kinase levels (recent) only if patients are on Statins / cholesterol medicines. Clinical assessment for cirrhosis (grade of portal fibrosis). If cirrhotic/suspected progression of portal fibrosis, exclusion of hepatocellular carcinoma based on appropriate imaging study = Ultrasound abdomen pelvis / Elastogram / liver biopsy / CT scan, whichever is appropriate and all past records. The duration of some treatment regimes is for 16 weeks or 24 weeks if cirrhosis has already set in. Urine Pregnancy test (in all women of childbearing age) (4 weeks old). If above tests are not done at place of origin, will be done at HCCI at first visit

17 Treatment & Evaluation Requirements by HCCI Medical Team during Subsequent Visits HCV RNA viral load quantitative testing (during 4 th visit) after finishing the 12 week regime or the 16 week regime, to demonstrate SUSTAINED VIROLOGICAL RESPONSE (SVR) and tell if its cured. If SVR is not seen at 12 th week, then the same test to be repeated after 24 weeks to demonstrate SVR or Virological relapse. The basic chemistry panel at week 4, week 8, week 12 during the regimen period will be serum ALT, AST, GGT, serum albumin, serum bilirubin (total, direct and indirect), INR,Prothrombin time, random blood sugar, and serum creatinine. More frequent monitoring is required if any of these results are not normal during the visits as per concerning results / trends on follow up. Other basic laboratory tests - Complete blood count with differentials at week 4, 8, 12, with more frequent monitoring as per concerning results / trends on follow up.

18 Treatment & Evaluation Requirements by HCCI Medical Team during Subsequent Visits Patients who achieve a sustained virologic response (SVR) after 12 weeks / 3 months of completing the regime and who do not have bridging fibrosis or cirrhosis do not require any specific follow-up for their HCV. Optionally HCV RNA viral load can be repeated after 6 months after the completion of treatment to confirm that the patient has maintained SVR or if SVR was not attained at the end of 12 weeks. Patients who fail to achieve SVR should be followed up for signs of progression of liver disease with Hepatologist. Patients with bridging fibrosis and cirrhosis (advanced or early liver disease) ( > grade 1 fibrosis) regardless of whether they attain SVR, warrant ongoing monitoring and surveillance due to risk of hepatocellular carcinoma or other complications of advanced liver disease.

19 Clinical Pharma-Travel Program: Hepatitis C Treatment On average, there is 94-96% success rate for patients with cirrhosis and 99% success rate with no cirrhosis with current newer directly acting anti- viral regimes (Harvoni regimes). However, there are many personal factors that influence treatment outcomes for individuals. To get a better understanding of how well you re likely to respond to current treatments would be based on the state of liver disease / co- morbidities / genotypes / treatment naïve / past history of virological failure / drug resistance, so be sure to follow your treatment. The success of your treatment can be improved by taking prescribed medicines regularly. How will response to treatment be monitored? Response to treatment is monitored by taking blood tests at intervals to measure the amount of virus in your blood. What the doctor will be looking for is a Sustained Virological Response (SVR). This means that the virus drops to undetectable levels at 12 th week when you finish the prescribed regime and remains undetectable for six months after you complete the treatment. Simply stated, it means you re cured.

20 Clinical Pharma-Travel Program: Hepatitis C Treatment Week 1: 2 Night Stay 28 Days Later: 1 Night Stay 28 Days Later: 1 Night Stay Within 1 Month after completin g 12 weeks regime: Final Review: 1-2 Night Stay HEP-C Package : $25,000 Package Inclusions: Hotel Stay (5-6 Nights Total- $400 USD per night) Air Fare Round Trip (Estimated Max of 1000 per round trip) Drugs, Consultation, and related lab investigations Does not include cost of treatment for any unrelated diagnosis or complications In the event lab investigations are not conducted at HCCI price of the package will be reduced by $1000

21 Concierge Service The team is a centralized, knowledge-based group of professionals addressing the needs, concerns & rights of the patient. With care as the teams central concept, they are the patient liaison: acting between patient, loved ones, health care providers, third party payers and administration to meet every patients needs and create a seamless, effortless flow of events.

22 Clinical Pharma-Travel Program: Hepatitis C Treatment Example of 90 days of treatment for Hepatitis C Traditional PBM Non-Traditional PBM Contract (PCSD Current PBM) Designated Medical Destinations $92,000 $62,000 $25,000* *includes initial assessment and consultation with physician, medication, lab work, hotel, air travel

23 Personal Prescription Importation The drug Lipitor was, for years, manufactured by its patent holder, Pfizer, in an FDA-registered facility in Ireland. The same Lipitor was exported for sale to the U.S. and Canadian markets, ending up in retail pharmacies in both countries. The Lipitor exported to the U.S. was packaged to meet FDA labelling guidelines, while the Lipitor exported to Canada was packaged to conform to the requirements of Health Canada s Therapeutic Products Division, Canada s FDA counterpart. Those Lipitor pills sold in Canadian pharmacies would be considered misbranded if brought into the U.S. and considered illegal if imported by Americans.

24 Personal Prescription Importation The use of FDA resources to provide comprehensive coverage of unapproved new drugs imported for personal use is generally not justified, however, the agency developed guidance in its Regulation Procedures Manual (RPM) entitled "Coverage of Personal Importations" (copy enclosed). This guidance sets forth the agency's enforcement priorities related to the personal importation of unapproved new drugs, with enforcement being focused on products apparently intended for the commercial market and on fraudulent products and those that pose an unreasonable health risk.

25 Personal Prescription Importation FDA Allowances: If you still choose to import prescription medications from outside the United States, be aware that FDA inspectors are allowed to use enforcement discretion to permit the importation of certain unapproved prescription medications for personal use, but that discretion includes these stipulations: The product is for personal use (90 day supply or less). The intended use is for a serious condition for which effective treatment may not be available domestically. There is no known commercialization or promotion to U.S. residents by those involved in the distribution of the product. The product does not represent an unreasonable risk. The individual seeking to import affirms in writing that it is for the patient s own use and give the name of the U.S. physician caring for them or that the therapy is a continuation of therapy begun by a foreign physician.

26 Program Excluded Prescriptions Narcotics and any other Controlled Substance as defined by the FDA Antibiotics or other Non Maintenance Medications including Stat Orders Stat Order: Immediate fill and initiation mandatory in Attending Physician s opinion) Biologics include but are not limited to a wide range of medicinal products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues and recombinant therapeutic proteins created by biological processes (as opposed to chemical). Drugs where frequent blood levels are required for titration with respect to narrow therapeutic ranges allied with close clinical observation. Drugs that require cold chain custody / refrigeration to preserve therapeutic efficacy, or any other drug that is supplied in a vial or includes hardware such as needles or syringes for administration Any Drug that is the subject of current or future FDA Consumer Safety Alerts or a Department of Homeland Security Alert or Process Change Additions and deletions to the Formulary will be made to reflect the current status of such alerts or process changes, with timely notification to the affected Member / Plan Sponsor

27 Cialis (Tadalafil) 20mg, 20 tablets, brand 4 $ 3, $ 1, $ 2, % Crestor (Rosuvastatin) 10mg, 90 tablets, Example Prescription Cost Comparison Product option Number of items PBM price Program Cost Savings Percenta ge savings Advair Diskus (Fluticasone/Salmeterol) 250mcg/50mcg, 3 x 60 dose diskuses, brand 2 $ 1, $ $ 1, % Ampyra (Dalfampridine) 10mg, 168 extended release tablets, brand 1 $ 5, $ 2, $ 2, % Arthrotec (Diclofenac/Misopristol) 75mg/200mcg, 180 tablets, brand 1 $ $ $ % Asacol HD (Mesalazine) 800mg, 336 tablets, brand 1 $ 2, $ $ 1, % Bystolic (Nebivolol) 5mg, 196 tablets, brand 1 $ $ $ % Bystolic (Nebivolol) 5mg, 84 tablets, brand 1 $ $ $ % Celebrex (Celecoxib) 200mg, 90 capsules, brand 2 $ 1, $ $ 1, %

28

29 Implementation Marketing mail order program Through health centers blasts, portal information page, flyers, etc Members can enroll by calling or register online Prescription can be faxed Shipping typically takes days Reminder notifications are sent around day 60 of a 90 day supply Invoice will be included and processes along with other health center supplier expenses

30

Hepatitis C Adjunct Therapy

Hepatitis C Adjunct Therapy Rule Category: Pharmaceutical ` Ref: No: 2016-PH-0002 Version Control: Version No. 1.0 Effective Date: 22-12-2016 Revision Date: 22-12-2017 Table of co Abstract Page Sc Pa Hepatitis C Adjunct Therapy Adjudication

More information

Topic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015

Topic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014

More information

Hepatitis C Update on New Treatments

Hepatitis C Update on New Treatments Hepatitis C Update on New Treatments Kevork M. Peltekian, MD, FRCPC 44th Annual Dalhousie Spring Refresher Course - Therapeutics April 5 - April 7, 2018 Halifax Convention Centre Disclosures Conflicts

More information

Molina Healthcare of Texas Hepatitis C Drugs (Medicaid)

Molina Healthcare of Texas Hepatitis C Drugs (Medicaid) Texas Standard Prior Authorization Form Addendum Molina Healthcare of Texas Hepatitis C Drugs (Medicaid) This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review

More information

Review: How to work up your patient with Hepatitis C

Review: How to work up your patient with Hepatitis C Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.

More information

Part I. Prior Authorization Criteria and Policy

Part I. Prior Authorization Criteria and Policy Texas Vendor Drug Program Antiviral Agents for Hepatitis C Virus Initial Authorization Request (Medicaid) Part I. Prior Authorization Criteria and Policy March 2018-E I. Eligibility 1. Patient is enrolled

More information

The New World of HCV Therapy

The New World of HCV Therapy HCV: Assessing the Patient Prior to Treatment: Diagnostic Testing and Strategy JORGE L. HERRERA M.D., MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE, MOBILE, AL The New World of HCV Therapy Interferon-free

More information

Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy

Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,

More information

Specialty Drugs in Workers Compensation

Specialty Drugs in Workers Compensation Specialty Drugs in Workers Compensation A GUIDE FOR CLAIMS HANDLERS Specialty Drugs Specialty drugs have been developed in response to demand for specialized medications for complex medical conditions.

More information

The New World of HCV Therapy

The New World of HCV Therapy HCV: Assessing the Patient Prior to Treatment: Diagnostic Testing and Strategy JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE, MOBILE, AL The New World of HCV Therapy Interferon-free

More information

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 4 Last Review Date: September 18, 2015 Daklinza Sovaldi Description

More information

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary April 1, 2017 Bulletin #165 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary Related Information for Prescribers: Only prescribers who have completed

More information

Coventry Health Care of Georgia, Inc.

Coventry Health Care of Georgia, Inc. Coventry Health Care of Georgia, Inc. PRESCRIPTION DRUG RIDER (for High Deductible Health Plans) This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health Plan

More information

PREPARED BY THE CENTER FOR HEALTH LAW AND POLICY INNOVATION OF HARVARD LAW SCHOOL

PREPARED BY THE CENTER FOR HEALTH LAW AND POLICY INNOVATION OF HARVARD LAW SCHOOL PREPARED BY THE CENTER FOR HEALTH LAW AND POLICY INNOVATION OF HARVARD LAW SCHOOL Hepatitis C Virus (HCV) in Prevalence + + Approximately 80,000 individuals in are living with hepatitis C virus (HCV).

More information

Get the most from your prescription plan

Get the most from your prescription plan Get the most from your prescription plan THE BALTIMORE CITY PUBLIC SCHOOLS Introducing Express Scripts What s Inside Your plan at a glance...2 Generics Preferred program...2 Prior authorization...3 Quantity

More information

Get the most from your prescription plan

Get the most from your prescription plan Get the most from your prescription plan THE BALTIMORE CITY PUBLIC SCHOOLS Introducing Express Scripts What s Inside Your plan at a glance...2 Generics Preferred program...2 Prior authorization...3 Quantity

More information

The Future is Here Now!

The Future is Here Now! HCV Treatment: Assessing the Patient Prior to Treatment. How Will This Change in the Future? JORGE L. HERRERA M.D., FACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE, MOBILE, AL The Future is Here Now!

More information

Exploring the risks of liver cancer after successful treatment for hepatitis C virus

Exploring the risks of liver cancer after successful treatment for hepatitis C virus CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Exploring the risks of liver cancer after successful treatment for hepatitis C virus 11 June 2013 In Canada and other high-income countries,

More information

Magellan Rx. A smarter approach to pharmacy benefits management

Magellan Rx. A smarter approach to pharmacy benefits management Magellan Rx A smarter approach to pharmacy benefits management Presented by: Cheri Caruso, VP of Sales, Magellan Rx Management Bryce Canfield, VP, Client Development, GoodRx A unique vision of care We

More information

FlexRx 6-Tier. SM Pharmacy Benefit Guide

FlexRx 6-Tier. SM Pharmacy Benefit Guide FlexRx 6-Tier SM Pharmacy Benefit Guide Welcome to FlexRx The AllWays Health Partners FlexRx SM program is built for choice, savings, and convenience with benefits including: Low-cost drug tier for many

More information

Coverage Period: 01/01/ /31/2018 Coverage for: Individual and/or Family Plan: Healthy Rewards HSA

Coverage Period: 01/01/ /31/2018 Coverage for: Individual and/or Family Plan: Healthy Rewards HSA This is only a summary of your GatorCare pharmacy benefits. If you would like detail about your coverage and costs, you can get the complete terms in the policy or plan document at gatorcare.magellanrx.com/member

More information

Hepatitis C Medications Hawaii PRIOR AUTHORIZATION REQUEST FORM

Hepatitis C Medications Hawaii PRIOR AUTHORIZATION REQUEST FORM Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form contains multiple pages. Please complete all pages to avoid a delay in our decision.

More information

Global reporting system for hepatitis (GRSH) project description

Global reporting system for hepatitis (GRSH) project description Global reporting system for hepatitis (GRSH) project description Contents 1. Background... 2 2. Target audience for this document... 2 3. Data to be reported through the Global Reporting System for Hepatitis...

More information

Prior Authorization. Drug Name (select from list of drugs shown) Viekira Pak (ombitasv-paritaprev-ritonav-dasabuv) Quantity Frequency Strength

Prior Authorization. Drug Name (select from list of drugs shown) Viekira Pak (ombitasv-paritaprev-ritonav-dasabuv) Quantity Frequency Strength 06/01/2016 Prior Authorization Aetna Better Health Texas Viekara Pak w or w/o Ribavirin First Fill (Med) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review

More information

Action Item for 2019 Review of Tool. Maintain (add include oral cavity) Maintain. Archive. Archive. 12 creatinine)

Action Item for 2019 Review of Tool. Maintain (add include oral cavity) Maintain. Archive. Archive. 12 creatinine) NEWLY DIAGNOSED/ NEW TO CARE PROGRAM SITE: REVIEWER(S): REVIEW DATE: CORE SERVICES Outpatient/Ambulatory Health Services Tool - 2018 (OLD) SECTION 1: CHART REVIEW Review for newly diagnosed HIV patients

More information

Your Prescription Card. Your guide for savings.

Your Prescription Card. Your guide for savings. CVS Caremark 620 Epsilon Drive Pittsburgh, PA 15238 4750-_PM 9501 E. Shea Blvd SCOTTSDALE, AZ 85260 Your Prescription Card. Your guide for savings. Dear Plan Member, Welcome to your new benefits. Attached

More information

2016: The State of HIV & Hepatitis C in the District

2016: The State of HIV & Hepatitis C in the District 2016: The State of HIV & Hepatitis C in the District Travis A. Gayles, MD, PhD Chief Medical Officer, HIV/AIDS, Hepatitis, STD, and TB Administration Division Chief, STD and TB Control February 29, 2016

More information

Pharmacy benefit guide

Pharmacy benefit guide FlexRx SM 5-Tier Pharmacy benefit guide 1 Welcome to FlexRx The NHP FlexRx SM program is built for choice, savings, and convenience with benefits including: Low-cost drug tier for many common medications

More information

1.0 Abstract. Title. Keywords

1.0 Abstract. Title. Keywords 1.0 Abstract Title Real World Evidence of the Effectiveness of Paritaprevir/r Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients with Chronic Hepatitis C - An Observational Study in Austria (REAL) Keywords

More information

HIVCare Programme 2017

HIVCare Programme 2017 HIVCare Programme 2017 Who we are LA Health Medical Scheme (referred to as 'the Scheme"), registration number 1145, is a non-profit organisation, registered with the Council for Medical Schemes. Discovery

More information

Olysio PegIntron Ribavirin

Olysio PegIntron Ribavirin Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.27 Subject: Olysio PegIntron Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio PegIntron

More information

Olysio Pegasys Ribavirin

Olysio Pegasys Ribavirin Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.28 Subject: Olysio Pegasys Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio Pegasys

More information

Medication, Travel and You

Medication, Travel and You Medication, Travel and You Zahra demolitor Pharmacist Owner Shoppers Drug Mart, Upper Tantallon January 17, 2013 1 Outline Drug Plans & Vacation Supplies How to pack medications Days supply you can take

More information

Prescription Drug Importation: Can it Help America's Seniors? Safety of Imported Medications: I-SaveRx Case Study

Prescription Drug Importation: Can it Help America's Seniors? Safety of Imported Medications: I-SaveRx Case Study Prescription Drug Importation: Can it Help America's Seniors? Safety of Imported Medications: I-SaveRx Case Study Presented By: Scott McKibbin Special Advocate For Prescription Drugs State Of Illinois

More information

Guidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

Guidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry DRAFT GUIDANCE This guidance

More information

Hepatitis C: Ribavirin/Pegylated Interferon combination therapy

Hepatitis C: Ribavirin/Pegylated Interferon combination therapy Hepatitis C: Ribavirin/Pegylated Interferon Introduction This information sheet is for people who want to know more about the ribavirin/pegylated interferon combination treatment for Hepatitis C (HCV).

More information

2016 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan

2016 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan 2016 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan Plan Details, Programs, and Policies Table of Contents Click on the links below to be taken to that

More information

Express Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011

Express Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011 BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)

More information

A&M Care Prescription Drug Program Express Scripts Holding Company. All Rights Reserved.

A&M Care Prescription Drug Program Express Scripts Holding Company. All Rights Reserved. A&M Care 2018 2019 Prescription Drug Program 1 Prescription Drug Benefits Annual Deductible Out of Pocket Maximum Access Options Retail 30 Day Supply: Refills allowed as prescribed. (Good option for new

More information

Transmission of HCV in the United States (CDC estimate)

Transmission of HCV in the United States (CDC estimate) Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong

More information

Ribavirin (Medicare Prior Authorization)

Ribavirin (Medicare Prior Authorization) Prior Authorization Form ARKANSAS BLUE CROSS AND BLUE SHIELD Medi-Pak Rx (PDP), Medi-Pak Advantage (PFFS), and Medi-Pak Advantage PPO Ribavirin (Medicare Prior Authorization) This fax machine is located

More information

Hepatitis C Basics. Michael Bailey Director of Programming, CATIE. Mary Choy Regional Health Education Coordinator, CATIE

Hepatitis C Basics. Michael Bailey Director of Programming, CATIE. Mary Choy Regional Health Education Coordinator, CATIE Hepatitis C Basics Michael Bailey Director of Programming, CATIE Mary Choy Regional Health Education Coordinator, CATIE CATIE Our History Learning Objectives 1) To learn about the basics of hepatitis C

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred

More information

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,

More information

Intron A (interferon alfa-2b) with ribavirin, (Moderiba, Rebetol, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)

Intron A (interferon alfa-2b) with ribavirin, (Moderiba, Rebetol, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.06 Subject: Intron A Ribavirin Page: 1 of 6 Last Review Date: March 18, 2016 Intron A Ribavirin Description

More information

Kaiser Permanente 2013 Sample Fee List

Kaiser Permanente 2013 Sample Fee List Kaiser Permanente 2013 Sample Fee List Members in any deductible plan 1 can use this list to help estimate their charges. COLORADO As your partner in health, we want to help you manage your health care

More information

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary April 1, 2018 Bulletin #170 ISSN 1923-0761 SASKATCHEWAN FMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary Related Information for Prescribers: The April 1, 2018 updates to existing

More information

Kaiser Permanente 2012 Sample Fee List Members in any deductible plan 1 can use this list to help estimate their charges.

Kaiser Permanente 2012 Sample Fee List Members in any deductible plan 1 can use this list to help estimate their charges. Kaiser Permanente 2012 Sample Fee List Members in any deductible plan 1 can use this list to help estimate their charges. NORTHERN CALIFORNIA As your partner in health, we want to help you manage your

More information

2018 Travelers Prescription Drug Plan High Deductible + HSA Plan

2018 Travelers Prescription Drug Plan High Deductible + HSA Plan 2018 Travelers Prescription Drug Plan High Deductible + HSA Plan Plan Details, Programs, and Policies Table of Contents Click on the links below to be taken to that section National Preferred Formulary

More information

JOHNS HOPKINS HEALTHCARE

JOHNS HOPKINS HEALTHCARE JOHNS HOPKINS HEALTHCARE Subject: Clinical Criteria for Hepatitis C (HCV) Therapy Department: Pharmacy Lines of Business: PPMCO Policy Number: MEDS92 Effective Date: 04/15/2015 Revision Date: 08/15/2015

More information

Update on Real-World Experience With HARVONI

Update on Real-World Experience With HARVONI Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data

More information

One State s Perspective on the Management of Hepatitis C Drugs. February 27, 2015 Pavel Lavitas, PharmD, BCPS Clinical Consultant Pharmacist

One State s Perspective on the Management of Hepatitis C Drugs. February 27, 2015 Pavel Lavitas, PharmD, BCPS Clinical Consultant Pharmacist One State s Perspective on the Management of Hepatitis C Drugs Pavel Lavitas, PharmD, BCPS Clinical Consultant Pharmacist Statement of Disclosure I have no relevant financial relationships that would be

More information

Getting started with Prime

Getting started with Prime Getting started with Prime How does a pharmacy plan work? When you visit your doctor, he or she may prescribe medicine for you. Here's how the plan works: Take your prescription and member ID card to the

More information

The Value of Walgreens

The Value of Walgreens The Value of Walgreens How Walgreens improves employer health plans through access, quality and lower costs Why millions of patients choose Walgreens And your options to move forward with Walgreens Walgreens

More information

Update to HMO Drug Formulary Tier Definitions. February 8, 2018

Update to HMO Drug Formulary Tier Definitions. February 8, 2018 Update to HMO Drug Formulary Tier Definitions February 8, 2018 Agenda 1 Overview of Current Drug Tiers 2 Proposed Drug Tiers for 2019 3 Impact to SFHSS and SFHSS Members 4 How the Drug Formulary Works

More information

Appendix 11 Roles and Responsibilities October, 2013 Page 1 of 5

Appendix 11 Roles and Responsibilities October, 2013 Page 1 of 5 October, 2013 Page 1 of 5 Exposed Person To present to a health care facility as soon as possible following the exposure (ideally within 2 hours). To answer assessment questions. (Refer to Appendix 15

More information

Intron A (interferon alfa-2b) with ribavirin, (Copegus, Moderiba, Rebetol, Ribapak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)

Intron A (interferon alfa-2b) with ribavirin, (Copegus, Moderiba, Rebetol, Ribapak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Intron A Ribavirin Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Ribavirin Description

More information

REQUEST FOR INFORMATION - HEPATITIS C TREATMENTS

REQUEST FOR INFORMATION - HEPATITIS C TREATMENTS 10 August 2015 REQUEST FOR INFORMATION - HEPATITIS C TREATMENTS PHARMAC is seeking information from suppliers of novel direct-acting antiviral agents (DAAs) for the treatment of hepatitis C. This Request

More information

Hepatitis C Virus (HCV)

Hepatitis C Virus (HCV) Clinical Practice Guidelines Hepatitis C Virus (HCV) OBJECTIVE The purpose is to guide the appropriate diagnosis and management of Hepatitis C Virus (HCV). GUIDELINE These are only guidelines, and are

More information

New Mexico Retiree Health Care Authority Medicare Part D Prescription Drug Program Express Scripts Holding Company. All Rights Reserved.

New Mexico Retiree Health Care Authority Medicare Part D Prescription Drug Program Express Scripts Holding Company. All Rights Reserved. New Mexico Retiree Health Care Authority Medicare Part D Prescription Drug Program 1 About Express Scripts Express Scripts is RHCA s chosen partner for administering your prescription plan We are a leading

More information

Texas Vendor Drug Program Specialty Drug List Process. February 2019

Texas Vendor Drug Program Specialty Drug List Process. February 2019 Texas Vendor Drug Program Specialty Drug List Process February 2019 Table of Contents Table of Contents...1 1 About the Specialty Drug List...2 1.1 Information for Pharmacies... 2 1.2 Information for Managed

More information

RECEIVING YOUR PERMANENT

RECEIVING YOUR PERMANENT 00001 JOHN Q SAMPLE 9501 E. Shea Blvd SCOTTSDALE, AZ 85260 3118-00001_PM City of Savannah 132 E. Broughton Street Savannah, GA 31401 THIS IS A ONE-TIME CARD TO BE USED UNTIL YOUR PERMANENT CARD ARRIVES

More information

Coverage Period: Coverage for: Plans: This is only a summary of your GatorCare pharmacy benefits. Coinsurance: you your Dependent Copayment: you

Coverage Period: Coverage for: Plans: This is only a summary of your GatorCare pharmacy benefits. Coinsurance: you your Dependent Copayment: you This is only a summary of your GatorCare pharmacy benefits. If you would like detail about your coverage and costs, you can get the complete terms in the policy or plan document at gatorcare.magellanrx.com/member

More information

Global reporting system for hepatitis (GRSH) data approval manual

Global reporting system for hepatitis (GRSH) data approval manual Global reporting system for hepatitis (GRSH) data approval manual Contents Acknowledgement... 1 General information... 2 1. Logging in... 2 2. Validating aggregated numbers in the reports application...

More information

Chronic Hepatitis C. Risk Factors

Chronic Hepatitis C. Risk Factors Chronic Hepatitis C The hepatitis C virus is one of the most important causes of chronic liver disease in the United States. Almost 4 million Americans or 1.8 percent of the U.S. population have an antibody

More information

Your Prescription Card. Your guide for savings.

Your Prescription Card. Your guide for savings. 3 Paragon Drive Montvale, NJ 07645 >00001 00001 001 P50708 _PM 7873 GROUP JOHN Q SAMPLE 9501 E. Shea Blvd SCOTTSDALE, AZ 85260 APDNCLDJDKDIFPAKHPANEMFK AJCLLKEBEKNJJBNMPKGOKIKK AMBPIBPEAKHEIOBKFGFBOMMK

More information

1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)

1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR) HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,

More information

Improving Mental Health Care: A Case Study

Improving Mental Health Care: A Case Study Improving Mental Health Care: A Case Study Why Improve Mental Health Care? Because the prevalence and costs of mental health problems are increasing in America despite the high prescribing of psychotropic

More information

The debut of velpatasvir for hepatitis C

The debut of velpatasvir for hepatitis C CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. The debut of velpatasvir for hepatitis C 23 November 2015 Hepatitis C virus (HCV) can be grouped into six major strains, or genotypes,

More information

Factsheet: Treatments for hepatitis C Direct Acting Antivirals (DAAs)

Factsheet: Treatments for hepatitis C Direct Acting Antivirals (DAAs) Factsheet: Treatments for hepatitis C Direct Acting Antivirals (DAAs) For more information about anything in this factsheet, phone the Hepatitis Infoline on 1800 703 003 or go to www.hepvic.org.au The

More information

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Harvoni Page: 1 of 7 Last Review Date: June 19, 2015 Harvoni Description Harvoni (ledipasvir &

More information

Pegylated Interferons and Ribavirins

Pegylated Interferons and Ribavirins Pegylated Interferons and Ribavirins Goal(s): Cover drugs only for those clients where there is evidence of effectiveness and safety Length of Authorization: 16 weeks plus 12-36 additional weeks or 12

More information

Dear Member: We look forward to serving you. Sincerely, Express Scripts

Dear Member: We look forward to serving you. Sincerely, Express Scripts Dear Member: Welcome to Express Scripts, the company Eastern Kentucky University has chosen to manage your prescription drug plan. As one of the nation s leading prescription benefit managers, Express

More information

Clinical Policy: Daclatasvir (Daklinza) Reference Number: CP.CPA.283 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Daclatasvir (Daklinza) Reference Number: CP.CPA.283 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: (Daklinza) Reference Number: CP.CPA.283 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for

More information

Cost effectiveness of sofosbuvir and ledipasvir (Harvoni ) in combination with other medicinal products for the treatment of hepatitis C infection

Cost effectiveness of sofosbuvir and ledipasvir (Harvoni ) in combination with other medicinal products for the treatment of hepatitis C infection Cost effectiveness of sofosbuvir and ledipasvir (Harvoni ) in combination with other medicinal products for the treatment of hepatitis C infection The NCPE has issued a recommendation regarding the cost

More information

EVALUATION OF ABNORMAL LIVER TESTS

EVALUATION OF ABNORMAL LIVER TESTS EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical

More information

Infergen Monotherapy. Infergen (interferon alfacon-1) Description

Infergen Monotherapy. Infergen (interferon alfacon-1) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.03 Subject: Infergen Monotherapy Page: 1 of 7 Last Review Date: March 13, 2014 Infergen Monotherapy

More information

CONTENTS. New Zealand s personal importation scheme for medicines. What is PrEP? Who will benefit from PrEP? Sex between men

CONTENTS. New Zealand s personal importation scheme for medicines. What is PrEP? Who will benefit from PrEP? Sex between men CONTENTS 4 What is PrEP? 6 Who will benefit from PrEP? Sex between men 7 Sex between men and women 8 What happens when I start on PrEP? 9 What if I want to stop using PrEP? Where can I get PrEP in New

More information

Clinical Policy: Simeprevir (Olysio) Reference Number: CP.CPA.289 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Simeprevir (Olysio) Reference Number: CP.CPA.289 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: (Olysio) Reference Number: CP.CPA.289 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

Vosevi (sofosbuvir/velpatasvir/voxilaprevir)

Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Policy Number: 5.01.646 Last Review: 10/2017 Origination: 10/2017 Next Review: 11/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide

More information

Market Distortions from the 340B Drug Pricing Program

Market Distortions from the 340B Drug Pricing Program Market Distortions from the 340B Drug Pricing Program Adam J. Fein, Ph.D. www.drugchannels.net @DrugChannels The opinions and views expressed in this presentation are those of the author and may not reflect

More information

Practical Approaches of Integrating HCV into HIV Care David Hachey, Pharm.D., BCPS, AAHIVP Professor Idaho State University

Practical Approaches of Integrating HCV into HIV Care David Hachey, Pharm.D., BCPS, AAHIVP Professor Idaho State University NORTHWEST AIDS EDUCATION AND TRAINING CENTER Practical Approaches of Integrating HCV into HIV Care David Hachey, Pharm.D., BCPS, AAHIVP Professor Idaho State University Presentation prepared by: David

More information

Restrictions to HCV Treatment in State Medicaid Programs

Restrictions to HCV Treatment in State Medicaid Programs Center for Health Law and Policy Innovation of Harvard Law School Restrictions to HCV Treatment in State Medicaid Programs Acknowledgements: We are in the midst of merging/comparing data with other analysts

More information

Kaiser Permanente 2015 Sample Fee List 1

Kaiser Permanente 2015 Sample Fee List 1 Kaiser Permanente 2015 Sample Fee List 1 SOUTHERN CALIFORNIA Knowing how much you can expect to pay for care and services can give you peace of mind. This Sample Fee List shows you estimated charges for

More information

Infergen (interferon alfacon-1) with Ribavirin (Copegus, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)

Infergen (interferon alfacon-1) with Ribavirin (Copegus, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.04 Subject: Infergen with Ribavirin Page: 1 of 8 Last Review Date: March 13, 2014 Infergen with Ribavirin

More information

PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S.

PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S. Speaker Brian K. Solow, MD, FAAFP Optum Life Sciences Irvine, CA, USA PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S. Brian K. Solow, MD, FAAFP Chief Medical Officer, Optum Life Sciences

More information

SIXTY-SEVENTH WORLD HEALTH ASSEMBLY A67/13 Provisional agenda item March Hepatitis

SIXTY-SEVENTH WORLD HEALTH ASSEMBLY A67/13 Provisional agenda item March Hepatitis SIXTY-SEVENTH WORLD HEALTH ASSEMBLY A67/13 Provisional agenda item 12.3 28 March 2014 Hepatitis Improving the health of patients with viral hepatitis Report by the Secretariat 1. The Executive Board at

More information

Clinical Policy: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) Reference Number: GA.PMN.25 Product: Medicaid Effective Date: 9/17

Clinical Policy: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) Reference Number: GA.PMN.25 Product: Medicaid Effective Date: 9/17 Clinical Policy: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) Reference Number: GA.PMN.25 Product: Medicaid Effective Date: 9/17 Last Review Date: 9/17 Revision Log See Important Reminder at the end of

More information

Hepatitis C Virus Clinical Criteria Update September 18, For: New York State Medicaid

Hepatitis C Virus Clinical Criteria Update September 18, For: New York State Medicaid Hepatitis C Virus Clinical Criteria Update September 18, 2014 For: New York State Medicaid 1 Purpose Characterize the place in therapy for the agents utilized for management of chronic hepatitis C (CHC)

More information

Up to $402,000. Insight HIV. Drug Class. 1.2 million people in the United States were living with HIV at the end of 2011 (most recent data).

Up to $402,000. Insight HIV. Drug Class. 1.2 million people in the United States were living with HIV at the end of 2011 (most recent data). HIV Background, new developments, key strategies Drug Class Insight INTRODUCTION Human Immunodeficiency Virus (HIV) is the virus that can lead to Acquired Immunodeficiency Syndrome, or AIDS. No safe and

More information

MArch The 2014 Drug Trend Report Highlights

MArch The 2014 Drug Trend Report Highlights MArch 2015 The 2014 Drug Report Highlights Highest Increase in U.S. Drug Spend Over Past Decade In 2014, the pharmacy landscape underwent a seismic change, and the budgetary impact to healthcare payers

More information

Objectives. Five Take Home Pearls. We Can Cure Hepatitis C. Hepatitis C Screening, Treatment and the Family Physician 10/15/2018

Objectives. Five Take Home Pearls. We Can Cure Hepatitis C. Hepatitis C Screening, Treatment and the Family Physician 10/15/2018 10/15/2018 Objectives Hepatitis C Screening, Treatment and the Family Physician Wayne Ghesquiere MD FRCPC Infectious Diseases & Internal Medicine Division of Infectious Diseases Victoria, BC At the end

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Ribavirin () Reference Number: CP.HNMC.252 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy

More information

Factsheet: New Treatments for hepatitis C Direct Acting Antivirals (DAAs)

Factsheet: New Treatments for hepatitis C Direct Acting Antivirals (DAAs) Factsheet: New Treatments for hepatitis C Direct Acting Antivirals (DAAs) For more information about anything in this factsheet, phone the Hepatitis Infoline on 1800 703 003 or go to www.hepvic.org.au

More information

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 7 Last Review Date: June 24, 2016 Daklinza Sovaldi Description Daklinza

More information

Polling Question # 3. DISCLOSURE STATEMENT Pharmacy Immunizations How to Stay Competitive and in Compliance LEARNING OBJECTIVES

Polling Question # 3. DISCLOSURE STATEMENT Pharmacy Immunizations How to Stay Competitive and in Compliance LEARNING OBJECTIVES DISCLOSURE STATEMENT Pharmacy Immunizations How to Stay Competitive and in Compliance R. JEFFREY HEDGES President & CEO I, Jeff Hedges, disclose that I am employed as a consultant at R.J. Hedges & Associates.

More information

Olysio Pegasys Ribavirin

Olysio Pegasys Ribavirin Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.28 Subject: Olysio Pegasys Ribavirin Page: 1 of 8 Last Review Date: December 18, 2017 Olysio Pegasys

More information